Physician profile

Erin Watson

Pain Medicine (Physical Medicine & Rehabilitation) · Conway, SC

NPI 1114139854

$9,110.42

in general payments reported to CMS, 2019-2025

42 companies · $1,355 in 2025

The $1,355 reported for 2025 was more than what 78% of Pain Medicine (Physical Medicine & Rehabilitation) providers received nationally (typical 2025 total: $400).

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$3,012.19

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Nevro Corp. $2,440.57 2019-2024 Senza
Boston Scientific Corporation $1,557.73 2019-2025 Wavewriter Alpha Prime 16, General - Pain Management
Medtronic, INC. $1,524.86 2022-2025 Intellis Adaptivestim, Inceptiv, Kyphon Express II Kyphopak Tray
Collegium Pharmaceutical, INC. $545.17 2019-2025 Xtampza, Belbuca
Radius Health, INC. $403.98 2019-2025 Tymlos
Nalu Medical, INC. $268.65 2022-2025 Nalu Neurostimulation System
Globus Medical, INC. $230.93 2025 Senza
Amgen INC. $212.87 2019-2024 Prolia, Evenity
Biodelivery Sciences International, INC. $155.33 2019-2021
Grt US Holding, INC. $147.29 2022
Takeda Pharmaceuticals U.S.A., INC. $132.99 2019-2024 Trintellix
Abbvie INC. $130.90 2021-2025 Ubrelvy, Qulipta
Abbott Laboratories $125.49 2019-2025 Eterna, Proclaim
Forte Bio-Pharma LLC $119.56 2020-2024 Prolate, Nalocet
Ethicon INC. $117.89 2021
Show all 42 companies
CompanyGeneral paymentsYearsTop products
Merck Sharp & Dohme LLC $110.40 2020-2023 Belsomra
Caris Mpi, INC. $80.00 2025 Mi Cancer Seek
Scilex Pharmaceuticals INC. $79.21 2019-2020
Spr Therapeutics, INC $67.10 2022-2025 Sprint Pns System
Assertio Therapeutics, INC. $66.08 2019
Si-Bone, INC. $60.98 2022-2023
Horizon Therapeutics Plc $52.36 2019
Biohaven Pharmaceutical Holding Company LTD. $49.31 2022
Pfizer INC. $44.73 2019-2023
Salix Pharmaceuticals, A Division of Bausch Health US, LLC $38.23 2022-2025 Relistor
Allergan, INC. $37.76 2019-2020
Pacira Pharmaceuticals Incorporated $33.26 2023-2025 Exparel, Iovera, Zilretta
Astrazeneca Pharmaceuticals LP $32.86 2019
Medtronic USA, INC. $28.31 2019
Avanos Medical $26.53 2022
Almatica Pharma LLC $20.80 2025 Teriparatide
Biohaven Pharmaceuticals, INC. $18.64 2021
Spinal Simplicity, LLC $18.51 2023 Ha Minuteman G3-R
Idorsia Pharmaceuticals US INC $17.81 2024 Quviviq
Biotronik Nro, INC. $17.24 2025 Prospera
Djo, LLC $15.07 2020
Mdd US Operations, LLC $14.33 2019
Eisai INC. $14.30 2021
Sentynl Therapeutics, INC. $13.87 2019
Arbor Pharmaceuticals, INC. $13.75 2021
Alexion Pharmaceuticals, INC. $12.73 2021
Teva Pharmaceuticals USA, INC. $12.04 2019

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Erin Watson

$9,110.42

in general payments reported 2019-2025

Years
2019-2025
Top company
Nevro Corp.
Context
The $1,355 reported for 2025 was more than what 78% of Pain Medicine (Physical Medicine & Rehabilitation) providers received nationally (typical 2025 total: $400).

https://glasscript.com/doctor/186750/erin-watson

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.